Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.
Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta
MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF MYRCLUDEX B, FOR HBV
Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program
Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds